is a labile, vasodilatory eicosanoid generated from arachidonic acid by cytochrome P450 epoxygenases. A series of robust, partially saturated analogues containing epoxide bioisosteres were synthesized and evaluated for relaxation of precontracted bovine coronary artery rings and for in vitro inhibition of soluble epoxide hydrolase (sEH). Depending upon the bioisostere and its position along the carbon chain, varying levels of vascular relaxation and/or sEH inhibition were observed. For example, oxamide 16 and N-iPr-amide 20 were comparable (ED 50 1.7 μM) to 14,15-EET as vasorelaxants but were approximately 10-35 times less potent as sEH inhibitors (IC 50 59 and 19 μM, respectively); unsubstituted urea 12 showed useful activity in both assays (ED 50 3.5 μM, IC 50 16 nM). These data reveal differential structural parameters for the two pharmacophores that could assist the development of potent and specific in vivo drug candidates.
Introduction
The oxidative metabolism of polyunsaturated fatty acids by the cytochrome P450 branch of the eicosanoid cascade generates, inter alia, one or more regioisomeric epoxides. 1 The best studied of these epoxanoids is all-cis-14,15-epoxyeicosatrienoic acid (14,15-EET a ), which is derived from arachidonic acid and ascribed an impressive array of cardiovascular, pulmonary, renal, and CNS roles.
2 Activation of a guanine nucleotide-binding protein (G-protein) is thought to play a pivotal role in many of the responses to 14,15-EET and often involves ADP-ribosylation of the G s R subunit. For instance, opening of vascular calcium-sensitive potassium channels by 14,15-EET is completely thwarted by guanosine 5 0 -O-(2-thio)diphosphate, a G-protein inhibitor, or by an antibody against G s R. 3 A reversible and abundant high-affinity binding site for 14,15-EET and its analogues has been identified 4 and shown to preferentially recognize the 14(R),15(S)-enantiomer. 5 The kinetic parameters of this binding site share many characteristics in common with the canonical prostanoid and leukotriene receptors, e.g., K d values in the low nanomolar range; 4 however, characterization of the putative EET receptor at the molecular level has been elusive. 6, 7 14,15-EET, in common with most eicosanoids, 8 is chemically and metabolically labile (Figure 1) . 9 Further transformations by enzymes of the cascade, 10 esterification, 11 conjugation, 12 β-oxidation, 13 chain elongation, and hydration by soluble epoxide hydrolase 14 (sEH) are well documented as inactivation or catabolic processes for 14,15-EET. The latter, in particular, appears to play a major role in regulating the intracellular levels of 14,15-EET, 15 whose in vivo half-life has been estimated as a few seconds to minutes. 16 Additionally, the proclivity of 14,15-EET toward auto-oxidation, a consequence of the 1,4-dienyl moieties present along the backbone, 17 introduces a further layer of complication and often necessitates storage and/or handling under an inert atmosphere. 9 Hence, a wide variety of factors combine to trammel the study of 14,15-EET and limit its potential therapeutic applications.
Structure-activity studies in the Falck and Campbell laboratories have addressed some of these limitations and led to the introduction of partially saturated 14,15-EET agonist analogues that obviate or minimize secondary metabolism as well as auto-oxidation. 18, 19 More recently, Hammock and colleagues have pioneered soluble epoxide hydrolase inhibition (sEHi) as an alternative, albeit indirect, strategy for pharmacological intervention in EET-dependent events. 20 This approach ostensibly 21 prolongs the eicosanoid's half-life, thereby elevating steady state levels of endogenous EETs as well as other epoxides. From an artful series of studies, lipophilic 1,3-disubstituted ureas emerged as especially efficacious in vitro and in vivo sEH inhibitors. 20 Advanced members of this genre show promise as first-in-class therapeutics for a variety of diseases including diabetes, inflammation, and hypertension. 22 In the present studies, we sought to develop and evaluate chimeric analogues that combine the more robust backbone of the partially saturated EET mimics with potential epoxide bioisosteres 23, 24 capable of functioning as stable 14,15-EET surrogates and/or as inhibitors of soluble epoxide hydrolase. 25 
Results and Discussion
Drawing inspiration from the aforementioned studies, analogue 1 was deemed a suitable point of departure for our investigation. Notably, 1 contains several key structural features, inter alia: (i) a partially saturated carbon backbone to avoid auto-oxidation 17 and LOX metabolism, 26 (ii) a cis-4 8,9
olefin thought to be essential for EET agonist activity, 18b and (iii) a sEH-resistant 1,3-disubstituted urea that we anticipated would function as a surrogate for the Δ 14, 15 -epoxide. 27 It was, thus, gratifying to find 1 mimics, albeit modestly, 14,15-EET as a vasorelaxant of precontracted bovine coronary artery rings (Table 1) . Additionally, 1 proved to be a low nanomolar inhibitor of recombinant human sEH. Methylation of the proximal urea nitrogen of 1 provided 2 but had little influence upon the vascular properties; as anticipated, methylation dramatically attenuated sEHi activity. 20 On the other hand, N-methylation of the distal urea nitrogen gave rise to regioisomer 3 and significantly improved EET mimicry while sEHi activity degraded sharply. The differences between these Nmethylated regioisomers for sEHi are similar to the differences observed previously with amide regioisomers. 15 Substitution of both nitrogens as in 4 did not prove additive with respect to VR but did further exacerbate the loss of sEHi. These data were the first convincing indications that EET agonist activity and sEHi could be at least partially differentiated in this compound series. Such differences may also be indicative of restricted orientation in the putative EET and sEH binding sites; further evidence can be found later in the series, e.g., Nmethylated amides 19 and 23. A lesser level of discrimination between the two activities could also be achieved by heteroatom replacement. 20 Thiourea 5 was equipotent with 14,15-EET across the entire concentration range of the vascular assay, while sEHi declined by a factor of 16 with respect to 1. On the other hand, replacement of either urea nitrogen with oxygen, i.e., 6 and 7, had relatively little influence on vessel tension but did blunt sEHi. In light of these data, it is tempting to speculate that hydrogen bonding or coordination to a metal center (e.g., Cu 2þ , Fe 2þ , or Zn 2þ ) might be an important contributor to binding at the putative EET vascular receptor.
We next turned our attention to the olefinic moiety and found vascular activity was diminished in trans-olefin 8 but not acetylene 9. Accommodation of a linear carbon chain or one that is bent in the natural cis-configuration, but not transgeometry, is consistent with a shallow binding pocket for this portion of the molecule. For sEHi, both 8 and 9 retained their low nanomolar potencies and were almost identical with that of the benchmark 1. Relocation of the cis-olefin to Δ 5,6 of the carbon chain (analogue 10) only modestly perturbed EET agonist activity and not at all for the related acetylene 11. This is unexpected given the regiodependency observed 18b in allied systems, e.g., cis-14,15-epoxy-eicosa-8(Z)-enoic acid is a 14,15-EET agonist while cis-14,15-epoxy-eicosa-5(Z)-enoic acid functions as a competitive antagonist. The dramatic slide in sEHi for 11, sans N-H, is consistent with established SAR for this pharmacophore. 20 Shifting the urea one position right (analogue 12) or left (analogue 13) relative to its placement in 1 improved VR with respect to 1, whereas displacement (accompanied by the cis-olefin) two positions further from the carboxylate, resembling an ω-3 fatty acid, was counterproductive (analogue 14), thus it is difficult to discern a trend in the series 12 f 1 f 13 f 14 correlating urea chain position and VR. On the other hand, the IC 50 for sEHi declined steadily following the same series. This appears generally consistent with the proposal 20 that "one hydrophobic group should be present on each side of the urea" and confirmed indications that a six-carbon n-alkyl chain is sufficient for low nanomolar inhibition. 20 Bioisosteric epoxide replacement by N-hydroxyurea and 1,4-oxamide led to 15 and 16, respectively, both of which showed acceptable VR at 10 μM. The latter was distinguished by a somewhat better ED 50 , yet its IC 50 for sEHi was more than 3 orders of magnitude greater than 1. In contrast to the outcome from conversion of 1 into 4, the N,N 0 -dimethylation of 16 to give 17 reduced its ability to relax the vessel while simultaneously moderating the loss of sEHi seen with 16.
The regioisomeric amide bioisosteres 18 and 22 displayed potentially useful sEHi activities but were lackluster EET mimics. The analogous N-methylated derivatives 19 and 23, respectively, as well as acetylene 21, lost potency except for a small improvement in the EC 50 of 19. sEHi by N-isopropyl 20 was likewise depressed, but the trend toward a more robust response in the vascular assay portended in 19 was clearly evident in this example. Whether the enhancement can be attributed to a hydrophobic binding pocket remains unclear at present.
A selection of nitrogen and oxygen heterocyclic bioisosteres, viz, triazole 24, furan 25, and 2-oxazoline 26, were prepared based upon the template in 1. They did not appear to offer any pharmacological advantage and were not pursued further. The loss of both VR and sEHi activities in the tetranor-ureas 27 and 28 is noteworthy given prior reports that chain-shortened 14,15-EETs retain much of their biological activity in the vasculature. 13 Formally, 27 and 28 can be envisioned as arising from 1 and 9, respectively, via two cycles of β-oxidation. 13 It will be of interest to determine if this is also a significant route of inactivation in vivo for the EET surrogates identified in this study.
Chemistry. The syntheses of thiourea 5, oxamide 16, and Nisopropylamide 20 are summarized in Scheme 1 and are representative of the methodology used to prepare the other analogues. Following literature precedent, 28 the dianion of commercial non-8-ynoic acid (29) was alkylated with 1 equiv of 2-(4-bromobutoxy)-tetrahydro-2H-pyran 29 (30) in THF/ HMPA (4:1). The resultant disubstituted acetylene 31 gave rise to alcohol 32 following acidic hydrolysis in methanol. Semihydrogenation over P-2 nickel created cis-olefin 33 that was subjected to azidation using diphenylphosphoryl azide (DPPA) under Mitsunobu conditions. Staudinger reduction of the product, azide 34, led to primary amine 35. Reaction of the latter with n-pentylisothiocyanate or a combination of 2-(butylamino)-2-oxoacetic acid 30 and 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) was unremarkable and furnished thiourea 38 and oxamide 40, respectively. Alternatively, 33 was converted with Ph 3 P/I 2 to iodide 36 that was then displaced with excess isopropylamine at 80°C. HATU-induced condensation of the product 37 with n-heptanoic acid delivered amide 42 in good overall yield. Saponification of 38, 40, and 42 afforded the corresponding free acids 5, 16, and 20, respectively. 
Conclusions
Herein, we have shown N-substituted ureas, oxamides, and N-substituted amides are suitable bioisosteres for fatty acid epoxides, whereas the urethanes, triazole, 2-oxazoline, furan, and secondary amides described above are not. In concert with literature observations, secondary amides were powerful sEH inhibitors as were 1,3-disubstituted ureas if the appendages are sufficiently lipophilic. Some epoxide surrogates behaved as both good EET agonists and powerful sEH inhibitors. Overall, there was no correlation between vascular relaxation and sEHi potencies, suggesting differential structural parameters for the two pharmacophores. It is anticipated that these dual-activity analogues could function additively and provide a platform for the development of the next generation of analogues intended for in vivo applications.
Experimental Section
General Procedures. Unless stated otherwise, yields refer to purified products and are not optimized. Final compounds were judged g95% pure by HPLC. All moisture-sensitive reactions were performed under an argon atmosphere using oven-dried glassware and anhydrous solvents. Anhydrous solvents were freshly distilled from sodium benzophenone ketyl, except for CH 2 Cl 2 , which was distilled from CaH 2 . Extracts were dried over anhydrous Na 2 SO 4 and filtered prior to removal of all volatiles under reduced pressure. Unless otherwise noted, commercially available materials were used without purification. Silica gel chromatography was performed using E. Merck silica gel 60 (240-400 mesh). Thin layer chromatography was performed using precoated plates purchased from E. Merck (silica gel 60 F254, 0.25 mm). Nuclear magnetic resonance (NMR) splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), and broad (br); the value of chemical shifts (δ) are given in ppm relative to residual solvent (chloroform δ=7.27 for 1 H NMR or δ=77.23 for proton decoupled 13 C NMR), and coupling constants (J) are given in hertz (Hz). The Michigan State University Mass Spectroscopy Facility or Medical College of Wisconsin provided high-resolution mass spectral analyses.
Methyl 13-Hydroxytridec-8-ynoate (32). n-Butyllithium (6.2 mL of 2.5 M solution in hexanes, 15.5 mmol) was added dropwise with stirring to a -78°C solution of non-8-ynoic acid (29) (1 g, 6.5 mmol, G. F. Smith Chem. Co.) in THF/HMPA (4:1, 50 mL) under an argon atmosphere. After 30 min, the reaction mixture was warmed to 0°C and maintained at this temperature for 2 h. After recooling to -78°C, a solution of 2-(4-bromobutoxy)-tetrahydro-2H-pyran 29 (30) (1.68 g, 7.14 mmol) in THF (10 mL) was added and the reaction temperature was slowly raised over 3 h to 23°C. After 12 h, the reaction mixture was quenched with saturated aq NH 4 Cl solution (5 mL) and the pH was adjusted to ∼4 using 1 M oxalic acid. The mixture was extracted with EtOAc (2 Â 50 mL), and the combined extracts were washed with water (2 Â 10 mL), brine (10 mL), dried, and concentrated under reduced pressure. Crude 31 was dissolved in methanol (20 mL) to which was added p-toluenesulfonic acid (PTSA, 25 mg). After 12 h, the solvent was evaporated and the residue was purified by SiO 2 column chromatography to give 32 (700 mg, 55%) as a colorless oil. TLC: EtOAc/hexanes (1:1), R f ∼ 0.55. (1 atm). After 15 min, freshly distilled ethylenediamine (56 μL, 0.833 mmol) was added to the black suspension, followed after a further 15 min by a solution of 32 (400 mg, 1.66 mmmol) in absolute EtOH (2 mL). After 1 h, the reaction mixture was diluted with Et 2 O (10 mL) and passed through a small bed of silica gel. The bed was rinsed with another portion of Et 2 O (10 mL). The combined ethereal filtrates were concentrated under reduced pressure to afford methyl 13-hydroxytridec-8(Z)-enoate (33) (34) . Diethyl azodicaboxylate (DEAD; 243 μL, 1.54 mmol) was added dropwise to a -20°C solution of PPh 3 (TPP; 405 mg, 1.54 mmol) in dry THF (10 mL) under an argon atmosphere. After 10 min, alcohol 33 (340 mg, 1.4 mmol) dissolved in dry THF (5 mL) was added dropwise. After 30 min, the reaction mixture was allowed to come to 0°C and diphenylphosphoryl azide (DPPA; 364 μL, 1.68 mmol) was added dropwise. After stirring for 4 h at rt, the reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3Â10 mL). The combined organic extracts were washed with brine (20 mL), dried, and concentrated under reduced pressure. The residue was purified by SiO 2 column chromatography eluting with 5% EtOAc/hexane to afford 34 (240 mg, 65% 
þ 241.3697, found 241.3705. Methyl 13-(3-Pentylthioureido)tridec-8(Z)-enoate (38). A solution of amine 35 (80 mg, 0.33 mmol) in THF (3 mL) was added dropwise to a stirring, 0°C solution of n-pentylisothiocyanate (80 mg, 0.29 mmol) in THF (4 mL). After 12 h at room temperature, all volatiles were removed under reduced pressure and the residue was purified by SiO 2 column chromatography eluting with 30% EtOAc/hexane to afford 38 (90 mg, 70%) as a colorless oil. TLC: EtOAc/hexanes (1:1), R f ∼ 0.65. 42 (m, 12H) , 0.88 (t, J=6.8 Hz, 3H). 13 
þ 371.2663, found 371.2669. 13-(3-n-Pentylthioureido)tridec-8(Z)-enoic Acid (5). LiOH (840 mL of a 1 M soln) was added to a 0°C solution of methyl ester 38 (80 mg, 0.21 mmol) in THF/H 2 O (4:1, 10 mL). After stirring at room temperature for 12 h, the THF was evaporated under reduced pressure, the remaining reaction mixture was (3 Â 10 mL) . The combined organic extracts were washed with brine (20 mL), dried, concentrated under reduced pressure, and the residue was purified by SiO 2 column chromatography eluting with EtOAc/hexane (1:1) to afford 5 (67 mg, 87%) as a colorless oil. TLC: 60% EtOAc/hexanes, R f ∼ 0.35; mp 84. 4 65 (m, 6H), 1.26-1.42 (m, 12H) , 0.88 (t, J=6.7 Hz, 3H). 13 
Article
þ 357.2267, found 357.2572. Methyl 13-(2-(n-Butylamino)-2-oxoacetamido)tridec-8(Z)-enoate (39). A mixture of 2-(n-butylamino)-2-oxoacetic acid 30 (60 mg, 0.413 mmol), amine 35 (119 mg, 0.496 mmol), and 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU; 172 mg, 0.455 mmol) in CH 2 Cl 2 (5 mL) was stirred at room temperature overnight and then all volatiles were removed in vacuo. The resultant residue was purified by SiO 2 column chromatography using 20% EtOAc/hexane as eluent to furnish oxamide 39 (112 mg, 76%) as a white solid, mp 112. . tetra-n-Butylammonium iodide (941 mg, 2.58 mmol) and DDQ (1.52 g, 2.58 mmol) were added in sequence to a solution of triphenylphosphine (676 mg, 2.58 mmol) and methyl 13-hydroxytridec-8(Z)-enoate (33) (520 mg, 2.15 mmol) in dry dichloromethane (30 mL) at room temperature. After 3 h, the reaction mixture was quenched with water (2 mL) and extracted with CH 2 Cl 2 (3 Â 15 mL). The combined extracts were dried, concentrated under reduced pressure, and the residue was purified by SiO 2 column chromatography using 3-6% EtOAc/hexanes as eluent to give methyl 13-iodotridec-8(Z)-enoate (36) (514 mg, 83%) as a pale-yellow oil. TLC: 10% EtOAc/hexanes, R f ∼ 0. were added sequentially to a room temperature solution of methyl 13-iodotridec-8(Z)-enoate (500 mg, 1.42 mmol) in dry tetrahydrofuran (7 mL). The mixture was heated in a sealed tube at 90°C for 12 h and then cooled to rt, diluted with water (2 mL), filtered, and the filtrate was extracted with ethyl acetate (3 Â 15 mL). The combined organic extracts were dried, concentrated under reduced pressure, and the residue was purified by SiO 2 column chromatography using a gradient from 2 to 5% MeOH/ CH 2 Cl 2 as eluent to give methyl 13- (N-isopropylamino) , 0.39 mmol) , and n-heptanoic acid (51 mg, 0.09 mmol) in dry DMF (3 mL). After 12 h, the reaction mixture was diluted with water (10 mL) and extracted with Et 2 O (3 Â 10 mL). The combined organic extracts were washed with brine, dried, and evaporated in vacuo. The residue was purified via SiO 2 column chromatography to give methyl 13-(isopropyl-n-heptanamido)tridec-8(Z)-enoate (40) Bioassays. The influence of eicosanoids and analogues on coronary vascular tone was measured by the induced changes in isometric tension of bovine coronary artery rings precontracted with the thromboxane-mimetic, U46619, as previously described.
18a,31 Synthetic 14,15-EET was used as a control. All assays were conducted in triplicate or greater and are means ( 10% SD of the reported value.
Recombinant human sEH was produced in a baculovirus expression system 32 and was purified by affinity chromatography. 33 Inhibition potencies (IC 50 s) were determined using a fluorescent-based assay. 34 Human sEH (∼1 nM) was incubated with inhibitors (0.4 < [I] final < 100000 nM) for 5 min in 25 mM bis-tris/HCl buffer (200 mL, pH 7.0) at 30°C before the substrate, cyano(2-methoxynaphthalen-6-yl)methyl trans-(3-phenyl-oxyyran-2-yl]methyl carbonate (CMNPC; [S] final =5 μM), was added. Activity was assessed by measuring the appearance of the fluorescent 6-methoxynaphthaldehyde product (λ em =330 nm, λ ex =465 nm) at 30°C during a 10 min incubation (Spectramax M2, Molecular Device, Inc., Sunnyvale, CA). 34 IC 50 s refer to the concentrations of inhibitor that reduced activity by 50% and are the averages of three replicates.
